Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation

• Published in: Scientific reports 2022-03, Vol.12 (1), p.3745-9, Article 3745
• Main Authors: Chiou, Wei-Ru, Lin, Po-Lin, Huang, Chun-Che, Chuang, Jen-Yu, Liu, Lawrence Yu-Min, Su, Min-I, Liao, Feng-Ching, Kuo, Jen-Yuan, Tsai, Cheng-Ting, Wu, Yih-Jer, Wang, Kuang-Te, Lee, Ying-Hsiang
• Format: Article
• Language: English
• Subjects: 692/4019; 692/4019/592; 692/4019/592/75; 692/4019/592/75/29; 692/4019/592/75/29/1309; Ablation; Anti-Arrhythmia Agents - adverse effects; Arrhythmia; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Cardiac arrhythmia; Catheter Ablation - adverse effects; Catheters; Congestive heart failure; Fibrillation; Heart failure; Heart Failure - drug therapy; Heart rate; Humanities and Social Sciences; Humans; Medical instruments; multidisciplinary; Multivariate analysis; Patients; Radiofrequency ablation; Retrospective Studies; Rivaroxaban - adverse effects; Science; Science (multidisciplinary); Stroke; Stroke - epidemiology; Stroke - etiology; Stroke - prevention & control; Thromboembolism; Thromboembolism - etiology; Treatment Outcome
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-022-07466-z

The current treatment paradigm for atrial fibrillation (AF) prioritizes rate control over rhythm control; however, rhythm control has shown benefits over other AF strategies. This study compares the outcomes of rivaroxaban with and without concomitant antiarrhythmic drugs (AADs), using propensity score matching to correct for statistical effects of baseline discrepancies. This multi-center retrospective study included 1,477 patients with non-permanent AF who took rivaroxaban for at least one month between 2011 and 2016 and had not received catheter ablation. Concomitant AAD use was compared against clinical outcome endpoints for effectiveness, safety, and major adverse cardiac events (MACE). Associations with concomitant AAD use were evaluated using multivariate Cox proportional hazard analyses. Patients were divided into two matched groups: rivaroxaban alone (n = 739) and with concomitant AADs (n = 738). The cumulative incidences of safety (p = 0.308), effectiveness (p = 0.583), and MACE (p = 0.754) were similar between the two groups, and multivariate analysis showed no significant differences. The new thromboembolism and all-cause death rates were higher in rivaroxaban alone (2.7% vs 0.8%, p = 0.005; and 10% vs. 6.9%, p = 0.032, respectively). The heart failure readmission rate was higher in the concomitant-AAD group (8.4% vs. 13.3%, p = 0.003). The concomitant use of rivaroxaban with AADs appears to be well-tolerated, with lower rates of thromboembolism and all-cause death, but is associated with more occurrences of congestive heart failure.